Developer docs
API playgroundTry for free, no card

Search company profiles

Ennovation Ventures

Full company profile

uuid002j42e

Namestring
Ennovation Ventures
Legal namestring
南京恩然瑞光投资管理中心(有限合伙)
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Ennovation Ventures (恩然创投) is a privately-held venture capital firm founded in 2015 and headquartered in Shanghai with a registered entity in Nanjing (南京恩然瑞光投资管理中心(有限合伙)). The firm specializes in equity investments across the global biopharmaceutical and medical health industry chain, focusing on revolutionary new technologies and products in life sciences, healthcare, and original innovation. Its portfolio of 65 companies spans oncology, inflammation/metabolism, gene therapy, AI-enabled healthcare, AI photonic computing, and adjacent deep-tech sectors including new materials and intelligent manufacturing.

The firm operates through 8 equity investment funds with assets under management exceeding 3 billion RMB. Its core product is capital allocation combined with hands-on post-investment support, sourced via a senior team whose backgrounds span pharmaceutical R&D (e.g., Managing Partner Chen Renhai's prior role at Shanghai Target Drug and Debug Pharmaceutical Group), clinical medicine, and prior VC partnerships at Nanjing Kaiyuan and Suzhou Kaifeng Zhengde. Distribution is direct: capital is deployed into portfolio companies across angel, pre-A, A, and A+ rounds, with co-investment partnerships including OrbiMed, Sequoia China, Hankang Capital, Bayer, and Aditum Bio.

The revenue model is standard for an Asian growth-stage VC: recurring management fees on multi-vintage fund AUM, supplemented by carried interest realized from portfolio company exits. Notable realized exits include Leads Biolabs (09887.HK, July 2025, where Ennovation was the 2015 angel and largest external institutional shareholder), TransThera Sciences (02617.HK, June 2025), and LIGHTELLIGENCE (01879.HK, April 2026, world's first AI photonic computing stock). The firm has no disclosed parent company, operates two offices (Shanghai HQ and Nanjing regional), and currently lists 8 named team members.

Short descriptiontext

Ennovation Ventures is a China-based venture capital firm founded in 2015 that invests across the global biopharmaceutical and healthcare industry chain, managing 8 funds with over 3 billion RMB AUM and a 65-company portfolio spanning oncology, biopharma, and AI-enabled healthcare.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersShanghai, China
HQ citystring
Shanghai
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital, biomedical investing, healthcare private equity, biopharmaceutical funding, equity investment funds
Industry1 code
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
NAICS code2 codes
  • All Other Financial Investment Activities52399
  • Other Investment Pools and Funds5259
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital / Private Equity (Biomedical and Healthcare)
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Fund Management
TypeLicensing Royalties
Description

Manages 8 equity investment funds with over 3 billion RMB in assets under management. Generates revenue through management fees and carried interest from portfolio company exits.

ennovationvc.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Ennovation Ventures is a venture capital firm that invests equity capital from 8 managed funds (over 3 billion RMB AUM) into early to mid-stage biomedical and healthcare companies globally. The firm acts as investor, partner, and co-founder to 65 portfolio companies spanning biopharmaceuticals, medical devices, AI healthcare, and adjacent sectors such as new materials and intelligent manufacturing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Multiple portfolio companies successfully listed on HKEX (Lightelligence, TransThera, Leads Biolabs)
+1 more record
Product overview1 text field

Ennovation Ventures is a venture capital firm established in 2015, specializing in biomedicine and healthcare investments. The firm does not offer traditional product or service offerings in the SaaS/application sense. Rather, it provides equity investment services through eight managed funds with over 3 billion RMB in assets, focusing on revolutionary new technologies and products in the global biomedicine and medical health industry chain. The firm has invested in 65 portfolio companies and serves as an investor, partner, and co-founder to innovative biopharmaceutical and healthcare enterprises.

Product and service2 records
1Equity Investment Fund Management (8 Funds)
CategoryVenture Capital Fund Management
Description

Management of 8 equity investment funds totaling over 3 billion RMB in AUM, deploying capital into early to mid-stage biomedical and healthcare companies. Revenue is generated through fund management fees and carried interest from portfolio company exits.

2Direct Equity Investment Services
CategoryPrivate Equity Investment
Description

Direct equity investment in portfolio companies across seed, angel, and growth stages, with the firm acting as investor, partner, and co-founder to 65 portfolio companies in biopharmaceuticals, medical devices, AI healthcare, new materials, and intelligent manufacturing.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1中国药科大学附属上海高博肿瘤医院 (Shanghai Gaobo Cancer Hospital)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-27
Description

Strategic cooperation with Immunophage for Phase II clinical trial of IPG7236. Professor Li Jin serves as PI.

ennovationvc.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-15
Description

Hope Medicine holds global exclusive license from Bayer for HMI-115 monoclonal antibody targeting prolactin receptor.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-07
Description

Aditum Bio and Leads Biolabs established Oblenio Bio for tri-specific T cell engager LBL-051 development. Deal worth up to $614 million including $35M upfront and milestones.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global healthcare-dedicated investment firm investing across venture, growth, and public stages in biopharma, medical devices, and diagnostics. Directly comparable as a healthcare-sector specialist VC; recently co-invested with Ennovation in Proviva Therapeutics' A+ round.

TypeBroad incumbent
Description

Large China-focused investment manager with a dedicated healthcare/biotech investing practice across venture and growth stages. Broader incumbent with substantially more AUM and global LP base, but overlapping Chinese biotech investment focus and HKEX exit pipeline.

TypeDirect peer
Description

China-based VC firm with a dedicated healthcare/biotech practice alongside technology investments. Directly comparable to Ennovation as a China-rooted investor focused on early-to-mid stage healthcare and life sciences companies, including biopharma and medical devices.

TypeBroad incumbent
Description

One of the earliest and largest China-focused venture firms, with a dedicated healthcare investment team covering biopharma, medical devices, and diagnostics. Broader incumbent comparable to Ennovation on Chinese healthcare/biotech early-stage deal-making and LP relationships.

TypeDirect peer
Description

Healthcare-focused investment firm with significant Asia-Pacific operations investing across venture and growth stages in biopharma, medical devices, and healthcare services. Directly comparable as a healthcare-sector specialist with comparable deal size and stage in Asia.

TypeEmerging player
Description

Strategic and corporate venture investors in the global biotech space that participate in rounds alongside specialist Chinese VCs. Comparable to Ennovation as co-investors in Chinese biotech (e.g., Bayer licensing relationship with portfolio company Hope Medicine indicates strategic capital adjacency).

TypeDirect peer
Description

Healthcare-dedicated investment firm focused on cross-border biotech investing with significant China exposure. Directly comparable as a healthcare-specialist investor operating between US and China biotech ecosystems with similar stage focus and exit pathways.

TypeBroad incumbent
Description

China-based investment platform with healthcare venture investing capabilities. Broader financial services incumbent with comparable Chinese biotech investment focus and access to HKEX exit opportunities through parent bank relationships.

TypeBroad incumbent
Description

Major China-focused venture and growth investor with active healthcare and biotech practice. Broader incumbent investing across multiple verticals, but with documented co-investment overlap with Ennovation (e.g., Proviva Therapeutics A+ round) and similar Chinese biotech IPO pipeline.

TypeDirect peer
Description

Asia-focused venture capital firm dedicated to life sciences and healthcare investments, with operations in China. Directly comparable to Ennovation as a sector-specialist healthcare/biotech VC based in Greater China with multiple portfolio IPOs and a similar early-to-growth stage investment strategy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment10 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ennovation Ventures

Venture Capital / Private Equity (Biomedical and Healthcare)ennovationvc.com

Ennovation Ventures is a China-based venture capital firm founded in 2015 that invests across the global biopharmaceutical and healthcare industry chain, managing 8 funds with over 3 billion RMB AUM and a 65-company portfolio spanning oncology, biopharma, and AI-enabled healthcare.

What Ennovation Ventures does

Ennovation Ventures (恩然创投) is a privately-held venture capital firm founded in 2015 and headquartered in Shanghai with a registered entity in Nanjing (南京恩然瑞光投资管理中心(有限合伙)). The firm specializes in equity investments across the global biopharmaceutical and medical health industry chain, focusing on revolutionary new technologies and products in life sciences, healthcare, and original innovation. Its portfolio of 65 companies spans oncology, inflammation/metabolism, gene therapy, AI-enabled healthcare, AI photonic computing, and adjacent deep-tech sectors including new materials and intelligent manufacturing.

The firm operates through 8 equity investment funds with assets under management exceeding 3 billion RMB. Its core product is capital allocation combined with hands-on post-investment support, sourced via a senior team whose backgrounds span pharmaceutical R&D (e.g., Managing Partner Chen Renhai's prior role at Shanghai Target Drug and Debug Pharmaceutical Group), clinical medicine, and prior VC partnerships at Nanjing Kaiyuan and Suzhou Kaifeng Zhengde. Distribution is direct: capital is deployed into portfolio companies across angel, pre-A, A, and A+ rounds, with co-investment partnerships including OrbiMed, Sequoia China, Hankang Capital, Bayer, and Aditum Bio.

The revenue model is standard for an Asian growth-stage VC: recurring management fees on multi-vintage fund AUM, supplemented by carried interest realized from portfolio company exits. Notable realized exits include Leads Biolabs (09887.HK, July 2025, where Ennovation was the 2015 angel and largest external institutional shareholder), TransThera Sciences (02617.HK, June 2025), and LIGHTELLIGENCE (01879.HK, April 2026, world's first AI photonic computing stock). The firm has no disclosed parent company, operates two offices (Shanghai HQ and Nanjing regional), and currently lists 8 named team members.

Ennovation Ventures firmographics

Firmographics
Name
Ennovation Ventures
Legal name
南京恩然瑞光投资管理中心(有限合伙)
Website
https://ennovationvc.com
Company type
Private
Founded year
2015
Operating status
Operating
Short description
Ennovation Ventures is a China-based venture capital firm founded in 2015 that invests across the global biopharmaceutical and healthcare industry chain, managing 8 funds with over 3 billion RMB AUM and a 65-company portfolio spanning oncology, biopharma, and AI-enabled healthcare.
Ownership category
akta.pro rank

Ennovation Ventures industry classification

Industry
Product category
Venture Capital / Private Equity (Biomedical and Healthcare)
NAICS
All Other Financial Investment Activities (52399), Other Investment Pools and Funds (5259)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)

Keywords

  • Venture capital
  • Biomedical investing
  • Healthcare private equity
  • Biopharmaceutical funding
  • Equity investment funds

Where Ennovation Ventures is headquartered

Location

Headquarters

HQ city
Shanghai
HQ country
China
HQ region
Asia

Offices2 records

Markets served

Ennovation Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

  1. Fund Management: Manages 8 equity investment funds with over 3 billion RMB in assets under management. Generates revenue through management fees and carried interest from portfolio company exits.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Ennovation Ventures product offering

Product offering

Core offering

Ennovation Ventures is a venture capital firm that invests equity capital from 8 managed funds (over 3 billion RMB AUM) into early to mid-stage biomedical and healthcare companies globally. The firm acts as investor, partner, and co-founder to 65 portfolio companies spanning biopharmaceuticals, medical devices, AI healthcare, and adjacent sectors such as new materials and intelligent manufacturing.

Product overview

Ennovation Ventures is a venture capital firm established in 2015, specializing in biomedicine and healthcare investments. The firm does not offer traditional product or service offerings in the SaaS/application sense. Rather, it provides equity investment services through eight managed funds with over 3 billion RMB in assets, focusing on revolutionary new technologies and products in the global biomedicine and medical health industry chain. The firm has invested in 65 portfolio companies and serves as an investor, partner, and co-founder to innovative biopharmaceutical and healthcare enterprises.

Differentiator

Problem solved

Functional benefit

Products and services

  • Equity Investment Fund Management (8 Funds) Management of 8 equity investment funds totaling over 3 billion RMB in AUM, deploying capital into early to mid-stage biomedical and healthcare companies. Revenue is generated through fund management fees and carried interest from portfolio company exits.
  • Direct Equity Investment Services Direct equity investment in portfolio companies across seed, angel, and growth stages, with the firm acting as investor, partner, and co-founder to 65 portfolio companies in biopharmaceuticals, medical devices, AI healthcare, new materials, and intelligent manufacturing.

Quantifiable outcome

  • Multiple portfolio companies successfully listed on HKEX (Lightelligence, TransThera, Leads Biolabs)
  • +1 more outcomes

Companies that use Ennovation Ventures

Customer profile

Named customers7 records

Segments1 record

Ideal customer profiles1 record

Ennovation Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Ennovation Ventures partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • 中国药科大学附属上海高博肿瘤医院 (Shanghai Gaobo Cancer Hospital)coreStrategic or Co-development Partner · 27 December 2024Strategic cooperation with Immunophage for Phase II clinical trial of IPG7236. Professor Li Jin serves as PI.
  • Bayer AGcoreStrategic or Co-development Partner · 15 November 2024Hope Medicine holds global exclusive license from Bayer for HMI-115 monoclonal antibody targeting prolactin receptor.
  • Aditum BiocoreStrategic or Co-development Partner · 7 November 2024Aditum Bio and Leads Biolabs established Oblenio Bio for tri-specific T cell engager LBL-051 development. Deal worth up to $614 million including $35M upfront and milestones.

Scale indicators4 records

Recent moves9 records

Expansion highlights5 records

Ennovation Ventures competitors and assessment

Company assessment

Direct peers

  • OrbiMed: Global healthcare-dedicated investment firm investing across venture, growth, and public stages in biopharma, medical devices, and diagnostics. Directly comparable as a healthcare-sector specialist VC; recently co-invested with Ennovation in Proviva Therapeutics' A+ round.
  • Qiming Venture Partners: China-based VC firm with a dedicated healthcare/biotech practice alongside technology investments. Directly comparable to Ennovation as a China-rooted investor focused on early-to-mid stage healthcare and life sciences companies, including biopharma and medical devices.
  • Vivo Capital: Healthcare-focused investment firm with significant Asia-Pacific operations investing across venture and growth stages in biopharma, medical devices, and healthcare services. Directly comparable as a healthcare-sector specialist with comparable deal size and stage in Asia.
  • Ally Bridge Group (汇桥资本): Healthcare-dedicated investment firm focused on cross-border biotech investing with significant China exposure. Directly comparable as a healthcare-specialist investor operating between US and China biotech ecosystems with similar stage focus and exit pathways.
  • LAV (礼来亚洲基金 / Lilly Asia Ventures): Asia-focused venture capital firm dedicated to life sciences and healthcare investments, with operations in China. Directly comparable to Ennovation as a sector-specialist healthcare/biotech VC based in Greater China with multiple portfolio IPOs and a similar early-to-growth stage investment strategy.

Broad incumbents

  • Hillhouse Capital (高瓴资本): Large China-focused investment manager with a dedicated healthcare/biotech investing practice across venture and growth stages. Broader incumbent with substantially more AUM and global LP base, but overlapping Chinese biotech investment focus and HKEX exit pipeline.
  • IDG Capital: One of the earliest and largest China-focused venture firms, with a dedicated healthcare investment team covering biopharma, medical devices, and diagnostics. Broader incumbent comparable to Ennovation on Chinese healthcare/biotech early-stage deal-making and LP relationships.
  • CMB International Capital (招银国际): China-based investment platform with healthcare venture investing capabilities. Broader financial services incumbent with comparable Chinese biotech investment focus and access to HKEX exit opportunities through parent bank relationships.
  • Sequoia China (红杉中国): Major China-focused venture and growth investor with active healthcare and biotech practice. Broader incumbent investing across multiple verticals, but with documented co-investment overlap with Ennovation (e.g., Proviva Therapeutics A+ round) and similar Chinese biotech IPO pipeline.

Emerging players

  • Boehringer Ingelheim Venture Fund / Strategic Healthcare Investors: Strategic and corporate venture investors in the global biotech space that participate in rounds alongside specialist Chinese VCs. Comparable to Ennovation as co-investors in Chinese biotech (e.g., Bayer licensing relationship with portfolio company Hope Medicine indicates strategic capital adjacency).

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Ennovation Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ennovation Ventures leadership team

Management profile

Number of profiles

Profiles7 records

Ennovation Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ennovation Ventures M&A and investment

M&A and investment

M&A

Investments10 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ennovation Ventures

What does Ennovation Ventures do?

Ennovation Ventures is a venture capital firm that invests equity capital from 8 managed funds (over 3 billion RMB AUM) into early to mid-stage biomedical and healthcare companies globally. The firm acts as investor, partner, and co-founder to 65 portfolio companies spanning biopharmaceuticals, medical devices, AI healthcare, and adjacent sectors such as new materials and intelligent manufacturing.

Is Ennovation Ventures a public or private company?

Ennovation Ventures is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Ennovation Ventures founded?

Ennovation Ventures was founded in 2015.

Where is Ennovation Ventures based?

Ennovation Ventures is headquartered in Shanghai, China, in the Asia region.

How does Ennovation Ventures make money?

One revenue line is on record: fund Management.

Who are Ennovation Ventures's main competitors?

Direct peers on record are OrbiMed, Qiming Venture Partners, Vivo Capital, Ally Bridge Group (汇桥资本) and LAV (礼来亚洲基金 / Lilly Asia Ventures). Broad incumbents are Hillhouse Capital (高瓴资本), IDG Capital, CMB International Capital (招银国际) and Sequoia China (红杉中国). Boehringer Ingelheim Venture Fund / Strategic Healthcare Investors is listed as an emerging player.

Does Ennovation Ventures have an API?

No public API is recorded for Ennovation Ventures.

What industry is Ennovation Ventures in?

Ennovation Ventures's product category is Venture Capital / Private Equity (Biomedical and Healthcare). Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 52399 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals